Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 19/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.78 |
| ▸ | FYN | P06241 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14653594 | 1.00 | PIM1 (0.80) | PIM1KCNH2FYN | |
| SCHEMBL103260 | 0.89 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL14638741 | 0.89 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL103197 | 0.88 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL138855 | 0.88 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL103173 | 0.88 | PIM1 (1.00) | PIM1KCNH2 | |
| SCHEMBL19986988 | 0.87 | PIM1 (0.84) | PIM1KCNH2 | |
| SCHEMBL19986920 | 0.87 | PIM1 (0.82) | PIM1KCNH2 | |
| SCHEMBL19986912 | 0.86 | PIM1 (0.82) | PIM1KCNH2 | |
| SCHEMBL22421515 | 0.86 | PIM1 (0.80) | PIM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA INC (US) | 2025-04-24 | — | — | US | disclosed |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3812387-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Sumitomo Dainippon Pharma Oncology, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| EP-3409278-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2020-09-16 | — | — | EP | disclosed |
| US-20200102313-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2020-04-02 | — | — | US | disclosed |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2019-03-07 | — | — | US | disclosed |
| EP-3409278-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | Tolero Pharmaceuticals, Inc. (US) | 2018-12-05 | — | — | EP | disclosed |
| EP-2734205-B1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS INC (US) | 2018-03-21 | — | — | EP | disclosed |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | SUMITOMO PHARMA AMERICA, INC. | 2017-01-05 | — | — | US | disclosed |
| US-9416132-B2 | Substituted imidazo[1,2-b]pyridazines as protein kinase inhibitors | TOLERO PHARMACEUTICALS, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | TOLERO PHARMACEUTICALS, INC. (US) | 2014-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10875864-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM2, PIM1, PIM3 | PIM1 2/4885KCNH2 1630/4885FYN 302/4885 |
| US-20190071446-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1832/4885FYN 273/4885 |
| US-20210238183-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1832/4885FYN 273/4885 |
| US-20250129085-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1832/4885FYN 273/4885 |
| US-20200102313-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1832/4885FYN 273/4885 |
| US-20140329807-A1 | HETEROCYCLIC PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1599/4885FYN 227/4885 |
| US-10392392-B2 | Substituted imidazo[1,2-B]pyridazines as protein kinase inhibitors | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1584/4885FYN 288/4885 |
| US-20250320217-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1832/4885FYN 273/4885 |
| US-20170002014-A1 | SUBSTITUTED IMIDAZO[1,2-B]PYRIDAZINES AS PROTEIN KINASE INHIBITORS | PIM1, PIM2, PIM3 | PIM1 1/4885KCNH2 1832/4885FYN 273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.